128P Comparative efficacy and safety of first-line maintenance therapies in advanced ovarian cancer: A biomarker-stratified Bayesian network meta-analysis of 16 phase III trials
The integration of poly(ADP-ribose) polymerase inhibitors (PARPi), immune checkpoint inhibitors, and anti-angiogenics has transformed first-line maintenance for advanced ovarian cancer (AOC), yet optimal regimens across biomarker profiles remain undefined. Aim is To evaluate the comparative efficacy and safety of frontline maintenance therapies across homologous recombination deficiency (HRD) and BRCA mutation (BRCAm) profiles in AOC.
Authors
- R. Falodia
- S. Sequeira
Institutions
- King Edward Memorial Hospital and Seth G.S. Medical College (IN)
- All India Institute of Medical Sciences Jodhpur (IN)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.108175
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00